Emerging studies suggest this peptide, a dual agonist targeting both the gut-brain axis and GIP , may offer a significant development for body loss . Initial patient trials have demonstrated substantial reductions in body tissue, possibly outperforming other body composition therapies . However , further assessment is necessary to fully understand